YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu S, Cheng P, Cheng Y. YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy. Frontiers In Pharmacology 2023, 14: 1244655. PMID: 37860121, PMCID: PMC10582333, DOI: 10.3389/fphar.2023.1244655.Peer-Reviewed Original ResearchCastration-resistant prostate cancerAR target genesActive compoundsAnti-prostate cancer drugProstate cancerSynergistic effectGlucocorticoid receptorPotential drug candidatesDrug discovery platformRA-VIILuciferase activityKey active compoundsGlucocorticoid receptor inhibitionProstate cancer managementNovel therapeutic agentsRA-VDrug candidatesCompoundsDeprivation therapySafety profileCancer deathExtra-terminal (BET) proteinsGR activityReceptor inhibitionAR inhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply